COMPOSITION, USE OF THE SAME, METHODS FOR PROPHYLAXY OR TREATMENT OF A STATE OR DISEASE, TO TREAT A DISEASE OR CONDITION, TO INHIBIT PROTEIN KINASE, TO MODULATE A CELL PROCESS, TO RELIEVE OR REDUCE THE INCIDENCE OR DISEASE, FOR DIAGNOSIS AND TREATMENT OF A DISEASE STATE OR CONDITION AND FOR MODULATING PROTEIN KINASE BE / OR PROTEIN KINASE A, AND PHARMACEUTICAL COMPOSITION
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL;CANCER RESEARCH TECHNOLOGY LIMITED;ASTEX THERAPEUTICS LIMITED;ASTRAZENECA AB
发明人:
STEVEN JOHN WOODHEAD,CHRISTOPHER HAMLETT,MARINUS LEENDERT VERDONK,DAVID WINTER WALKER,HANNAH FIONA SORE,IAN COLLINS,JOHN CALDWELL,TATIANA FARIA DA FONSECA MCHARDY,RICHARD WILLIAM ARTHUR LUKE,ZBIGNIEW
申请号：
BRPI0721124
公开号：
BRPI0721124A2
申请日:
2007.12.20
申请国别(地区):
BR
年份:
2014
代理人:
摘要：
The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R)x N * (GP1) (2) GP is a group GP2: 10 (R)r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members； the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members； and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims
